Welcome to our dedicated page for agilon health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
agilon health, inc. filings document the company’s value-based healthcare services business, governance matters, capital structure and operating results. Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, executive appointment and compensation arrangements, and material definitive agreements, including amendments to the company’s credit agreement.
Definitive proxy statements cover shareholder voting matters, board governance and executive compensation. The filing record also includes capital-structure disclosures, such as a certificate amendment related to a reverse stock split of common stock, along with risk-factor and material-event disclosures relevant to agilon’s physician-partnership model and payor contracting environment.
Capital World Investors reports beneficial ownership of 10,852,943 shares of agilon health, representing 2.6% of the 414,423,149 shares outstanding. The filing states that Capital World Investors holds sole voting and dispositive power over those shares, and that the securities are held in the ordinary course of business and not for the purpose of influencing control of the issuer. The disclosure is presented as an amendment to a prior Schedule 13G filing and identifies Capital World Investors as the reporting entity and an investment adviser organization.
North Peak disclosed a passive stake in agilon health totaling 21,536,679 shares, representing 5.2% of outstanding common stock based on 414,423,149 shares.
The filing is a joint Schedule 13G dated 08/22/2025 showing ownership across related entities: North Peak Capital Partners, LP (1,247,465 shares), North Peak Capital Partners II, LP (10,585,833 shares), North Peak Capital Alpha Fund, LP (5,564,235 shares) and North Peak Capital Ultra Fund, LP (878,841 shares). Certain affiliates and principals (North Peak Capital Management, North Peak GP, and Jeremy and Michael Kahan) report shared voting or dispositive power over 18,276,374 shares (4.4%).
The statement clarifies the holdings are reported as passive (Schedule 13G) and includes a joint filing agreement; it does not state any intent to influence control of the issuer.
Form 4 filed for agilon health, inc. (AGL) reports a transaction by Timothy Gertsch, identified as an officer (Chief Accounting Officer) and director. The filing records a transaction dated 08/16/2025 coded "F" showing "406(1) D" at a price of $1.11 and reports 114,752 shares beneficially owned following the reported transaction. The form's explanation states that the "406" figure represents shares withheld by the issuer to satisfy income tax withholding in connection with net settlement of restricted stock units and that this withholding "does not represent a sale." The form is signed by an attorney-in-fact on 08/19/2025.
Capital World Investors reports a material stake in agilon health. The filing discloses beneficial ownership of 45,570,601 shares of agilon health common stock, equal to 11.0% of the 413,951,779 shares believed outstanding. The filer reports sole voting and sole dispositive power over all reported shares.
The disclosure identifies Capital World Investors as a division of Capital Research and Management Company together with its investment management subsidiaries and affiliates that collectively provide investment services under the Capital World Investors name. The statement affirms the securities are held in the ordinary course of business and are not held to change or influence control of the issuer. Item 6 lists American Funds Fundamental Investors in the context of ownership on behalf of another person.
Capital International Investors reported beneficial ownership of 9,892,742 shares of agilon health common stock, equal to 2.4% of 413,951,779 shares outstanding. CII is presented as a division of Capital Research and Management Company and affiliated investment management entities and states it has sole voting and sole dispositive power over those 9,892,742 shares with no shared power. The disclosure is filed on a Schedule 13G/A as an IA (investment adviser) and the filing notes this is an ownership position of 5% or less. The signer certifies the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FMR LLC (Fidelity) and Chair & CEO Abigail P. Johnson filed a Schedule 13G reporting a passive 9.4 % stake in agilon health, Inc. (AGL) as of 30 Jun 2025. The group beneficially owns 38,760,723 common shares, with FMR holding sole voting power over 38,742,056 shares and sole dispositive power over the full position; no shared voting or dispositive rights were disclosed. The filing was made under Rule 13d-1(b) for a parent holding company/control person, indicating the shares were acquired in the ordinary course of business and not to influence control of the issuer. No other individual investor within the Fidelity complex owns more than 5 % of AGL. The declaration, signed 5 Aug 2025 by attorney-in-fact Richard Bourgelas, certifies passive intent. While the disclosure does not signal corporate action, it materially raises AGL’s institutional ownership base and may enhance liquidity and market visibility.
agilon health (AGL) filed an 8-K covering multiple governance and disclosure items. On 29 Jul 2025 Chief Executive Officer & President Steven J. Sell resigned, classified as a termination without “cause.” He will receive contractual severance; details reference the 2025 proxy. The Board size falls to seven and an “Office of the Chairman” is established, led by Executive Chairman Ron Williams and six other senior officers; CFO Jeffrey Schwaneke and Chief Markets Officer Benjamin Shaker become interim principal executive officers.
Concurrently, the Board amended and restated the company by-laws to redefine certain officer roles and incorporate technical Delaware law updates (filed as Ex. 3.1). Under Items 2.02 and 7.01 the company furnished—but did not file—press releases and an investor presentation (Exs. 99.1-99.3) containing Q2 2025 results and leadership changes; specific financial metrics are not included in this filing.
No related-party transactions were disclosed beyond existing indemnification agreements. Overall, the filing highlights a sudden CEO departure, interim leadership measures, and administrative charter updates.